Author

Clemens Leitgeb

Observed names: C Leitgeb, C. Leitgeb

Observed institution: Wilhelminen Hospital

OpenAlex ID: A5046839590

Prediction of response to erythropoietin treatment in chronic anemia of cancer [see comments]

1994 · H Ludwig, E Fritz, et al. · Blood · 192

Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin

1994 · Clemens Leitgeb, Martin Pecherstorfer, et al. · Cancer · 165

Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy

1995 · Heinz Ludwig, Even Sundal, et al. · Cancer · 133

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

2013 · Heinz Ludwig, Hedwig Kasparu, et al. · Blood · 100

Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors

1993 · H. Ludwig, E. Fritz, et al. · Annals of Oncology · 93

PDF

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

2017 · H Ludwig, K Weisel, et al. · Leukemia · 81

PDF

Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma

1993 · Heinz Ludwig, Martin Pecherstorfer, et al. · Stem Cells · 33

Erythropoietin treatment of chronic anaemia of cancer

1993 · H. Ludwig, C. Leitgeb, et al. · European Journal of Cancer · 21

Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas

2014 · Kira Brämswig, Ferdinand Ploner, et al. · Anti-Cancer Drugs · 11

Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials

2026 · Simon Udovica, Rupert Bartsch, et al. · npj Breast Cancer · 7

PDF

Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated

2012 · Heinz Ludwig, Hedwig Kasparu, et al. · Blood · 6

Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians

2011 · Heinz Ludwig, Hedwig Kasparu, et al. · Blood · 5

[Quality of life and cytokines in oncological therapy].

1998 · C Leitgeb · PubMed · 2

Erythropoietin for chronic anemia of cancer: Treatment results and prediction of responsiveness

1995 · H. Ludwig, E. Fritz, et al. · European Journal of Cancer · 1

Impact of Number of Previous Treatment Lines and Pre-Treatment with Bortezomib or Lenalidomide on Efficacy of Bortezomib-Bendamustine-Dexamethasone (BBD) in Patients with Relapsed/Refractory Multiple Myeloma (MM)

2012 · H. Ludwig, H. Kasparu, et al. · Annals of Oncology

Continuous treatment with lenalidomide in multiple myeloma: a case report

2012 · E. Müldür, A. Weißmann, et al. · memo - Magazine of European Medical Oncology

PDF

Organisationsstrukturen der Onkologie im deutschsprachigen Raum und Europa

2006 · U. Wedding, K. Höffken, et al. · Springer eBooks

Patients perceptions of cancer-related fatigue: results of an austrian assessment survey

2001 · W. Halbritter, C. Leitgeb, et al. · European Journal of Cancer

Erythropoetin bei chronischen Tumoranämien

1993 · H. Ludwig, C. Leitgeb, et al. · Springer eBooks

Abstract

1992 · Ch. Mache, Ch. Urban, et al. · Annals of Hematology

PDF

Works count: 20

Citation count: 850

H-index: 9

I10-index: 9